Vanda Pharmaceuticals | VNDA - Собственный капитал и резервы





Собственный капитал и резервы Изменить Дата
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
Akebia Therapeutics USD 25.02M 2.36M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 465.53M 148.45M 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Halozyme Therapeutics USD 143.54M 76.09M 2026-06
Heron Therapeutics USD 6.91M 2.23M 2026-06
Insmed USD 757.49M 52.64M 2026-06
J&J USD 84.97B 3.78B 2026-06
Lexicon Pharmaceuticals USD 202.86M 95.32M 2026-03
Ligand Pharmaceuticals USD 967.52M 29.81M 2026-06
Merck USD 41.93B 3.94B 2026-06
Minerva Neurosciences USD -140.75M 106.17M 2025-12
Moderna USD 6.76B 647M 2026-06
Novartis USD 38.93B 7.2B 2026-03
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD -165.36M 15.1M 2026-06
Puma Biotechnology USD 115.27M 10.55M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Sanofi EUR 69.57B 3.24B 2026-06
Takeda JPY 7.56T 215.7B 2026-06
Teva Pharmaceutical Industries USD 7.75B 475M 2026-06
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12
Veracyte USD 1.39B 44M 2026-06